Developer docs
API playgroundTry for free, no card

Search company profiles

Pherecydes Pharma

Full company profile

uuid0003efx

Namestring
Pherecydes Pharma
Legal namestring
Pherecydes Pharma
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Pherecydes Pharma is a French private biotechnology company founded in 2006 and headquartered in Romainville, France, that develops precision phage therapy — bacteriophage-based treatments — for antibiotic-resistant bacterial infections. Its primary stated program is the PhagECOLI project, a three-year initiative targeting resistant Escherichia coli infections through a precision phage therapy approach, conducted in collaboration with the French Alternative Energies and Atomic Energy Commission (CEA) and funded by a €2 million Bpifrance grant awarded in January 2022.

The company's product strategy centers on developing phage-based therapeutic candidates intended for use by hospitals and healthcare facilities treating patients with antibiotic-resistant infections, where conventional antibiotics have limited efficacy. Its underlying technology relies on the selection and application of phages tailored to specific resistant pathogens, with the proprietary phage-for-E. coli pipeline cited as the core technical differentiator. The company operates with a small team (11–50 employees) led by CEO Guy Charles Fanneau de La Horie, COO Thibaut du Fayet, and Scientific Director Cindy Fevre.

Pherecydes Pharma's business model is research-stage rather than commercial: it does not disclose pricing, customers, or revenue, and its funding history — roughly $19 million across five equity-style rounds from 2012 to 2018, plus the 2022 Bpifrance grant — indicates reliance on a mix of venture capital (GO CAPITAL, Ace Capital Partners, Auriga Partners, Karista, Omnes Capital, FaDièse) and non-dilutive public funding. Capital is allocated to advance its phage therapy pipeline, with monetization contingent on future clinical development, regulatory milestones, or licensing deals that are not documented in the available data.

Short descriptiontext

Pherecydes Pharma is a French private biotech developing precision phage therapy for antibiotic-resistant bacterial infections, primarily targeting resistant E. coli for hospital and healthcare use. It collaborates with CEA and is funded by venture capital and a Bpifrance grant.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNantes, France
HQ citystring
Nantes
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
phage therapy, precision antimicrobials, antibiotic resistance, bacteriophage treatments, biopharmaceutical research
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals (Phage Therapy)
Social media profiles2 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pherecydes Pharma is a French biotechnology company developing precision phage therapy (bacteriophage-based treatments) to combat antibiotic-resistant bacterial infections. Its lead research program, the PhagECOLI project, focuses on creating phage-based tools and treatments targeting resistant Escherichia coli infections. The company is at the R&D stage, conducting research in collaboration with CEA and funded by Bpifrance and venture capital investors.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pherecydes Pharma is a biotechnology company focused on precision phage therapy for treating resistant bacterial infections. The company develops phage-based treatments, with its primary research activity centered on the PhagECOLI project funded by Bpifrance, which aims to develop new tools and treatments for resistant E. coli infections using precision phage therapy.

Product and service1 record
1PhagECOLI
CategoryPhage-based antimicrobial therapy
Description

A three-year research program developing precision phage therapy tools and treatments for antibiotic-resistant Escherichia coli infections, conducted in partnership with CEA and funded by a €2 million grant from Bpifrance.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pherecydes Pharma collaborates with CEA on the PhagECOLI project, a three-year research initiative focused on developing new tools and treatments for resistant E. coli infections using precision phage therapy. The partnership leverages CEA's research capabilities in atomic energy and alternative energies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage phage therapy company developing phage-based treatments for chronic and acute bacterial infections. Directly comparable to Pherecydes in modality (precision phage therapy), target indications (resistant bacterial infections), and stage of development.

TypeDirect peer
Description

Clinical-stage company developing engineered bacteriophage therapies, including CRISPR-enhanced phages, for antibiotic-resistant infections. Direct peer in modality, AMR focus, and clinical-stage development.

TypeDirect peer
Description

Clinical-stage phage therapy company developing both natural and engineered phage cocktails for resistant bacterial infections including Staphylococcus aureus and Pseudomonas aeruginosa. Direct peer in phage modality and AMR focus.

TypeDirect peer
Description

Biotech developing direct lytic agents and phage-derived lysins for serious antibiotic-resistant infections. Comparable to Pherecydes in pursuing novel antimicrobial modalities against resistant bacterial pathogens.

TypeRegional player
Description

Portugal-based clinical-stage phage therapy developer working on personalized and fixed phage cocktails for resistant bacterial infections. Comparable to Pherecydes in modality and AMR focus, but operating primarily in Southern Europe/Portugal rather than France.

TypeDirect peer
Description

Developer of engineered phage-based therapeutics (eligobiotics) targeting specific bacterial pathogens. Comparable to Pherecydes in precision phage platform approach and focus on selectively eradicating disease-causing bacteria.

7Phagelux
TypeEmerging player
Description

Phage-based biotech developing therapeutic and agricultural applications of bacteriophages. Comparable to Pherecydes in phage platform technology, though with a broader agricultural/industrial portfolio alongside human health.

TypeEmerging player
Description

Developer of phage-based products including Gladskin for skin conditions and food-safety applications. Comparable to Pherecydes in underlying phage technology platform but currently focused on consumer/dermatology rather than systemic resistant infections.

TypeEmerging player
Description

Biotech using CRISPR-engineered phage and microbial approaches to precisely target bacteria. Comparable to Pherecydes in using precision phage-derived mechanisms to address resistant bacterial populations.

10Cytophage Technologies
TypeEmerging player
Description

Canadian biotech developing synthetic biology-based phage products targeting resistant bacteria in human and animal health. Comparable to Pherecydes in leveraging engineered phage approaches against AMR pathogens.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pherecydes Pharma

Biopharmaceuticals (Phage Therapy)pherecydes-pharma.com

Pherecydes Pharma is a French private biotech developing precision phage therapy for antibiotic-resistant bacterial infections, primarily targeting resistant E. coli for hospital and healthcare use. It collaborates with CEA and is funded by venture capital and a Bpifrance grant.

What Pherecydes Pharma does

Pherecydes Pharma is a French private biotechnology company founded in 2006 and headquartered in Romainville, France, that develops precision phage therapy — bacteriophage-based treatments — for antibiotic-resistant bacterial infections. Its primary stated program is the PhagECOLI project, a three-year initiative targeting resistant Escherichia coli infections through a precision phage therapy approach, conducted in collaboration with the French Alternative Energies and Atomic Energy Commission (CEA) and funded by a €2 million Bpifrance grant awarded in January 2022.

The company's product strategy centers on developing phage-based therapeutic candidates intended for use by hospitals and healthcare facilities treating patients with antibiotic-resistant infections, where conventional antibiotics have limited efficacy. Its underlying technology relies on the selection and application of phages tailored to specific resistant pathogens, with the proprietary phage-for-E. coli pipeline cited as the core technical differentiator. The company operates with a small team (11–50 employees) led by CEO Guy Charles Fanneau de La Horie, COO Thibaut du Fayet, and Scientific Director Cindy Fevre.

Pherecydes Pharma's business model is research-stage rather than commercial: it does not disclose pricing, customers, or revenue, and its funding history — roughly $19 million across five equity-style rounds from 2012 to 2018, plus the 2022 Bpifrance grant — indicates reliance on a mix of venture capital (GO CAPITAL, Ace Capital Partners, Auriga Partners, Karista, Omnes Capital, FaDièse) and non-dilutive public funding. Capital is allocated to advance its phage therapy pipeline, with monetization contingent on future clinical development, regulatory milestones, or licensing deals that are not documented in the available data.

Pherecydes Pharma firmographics

Firmographics
Name
Pherecydes Pharma
Legal name
Pherecydes Pharma
Website
https://pherecydes-pharma.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Pherecydes Pharma is a French private biotech developing precision phage therapy for antibiotic-resistant bacterial infections, primarily targeting resistant E. coli for hospital and healthcare use. It collaborates with CEA and is funded by venture capital and a Bpifrance grant.
Ownership category
akta.pro rank

Pherecydes Pharma industry classification

Industry
Product category
Biopharmaceuticals (Phage Therapy)
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Phage therapy
  • Precision antimicrobials
  • Antibiotic resistance
  • Bacteriophage treatments
  • Biopharmaceutical research

Where Pherecydes Pharma is headquartered

Location

Headquarters

HQ city
Nantes
HQ country
France
HQ region
Europe

Markets served

Pherecydes Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Pherecydes Pharma product offering

Product offering

Core offering

Pherecydes Pharma is a French biotechnology company developing precision phage therapy (bacteriophage-based treatments) to combat antibiotic-resistant bacterial infections. Its lead research program, the PhagECOLI project, focuses on creating phage-based tools and treatments targeting resistant Escherichia coli infections. The company is at the R&D stage, conducting research in collaboration with CEA and funded by Bpifrance and venture capital investors.

Product overview

Pherecydes Pharma is a biotechnology company focused on precision phage therapy for treating resistant bacterial infections. The company develops phage-based treatments, with its primary research activity centered on the PhagECOLI project funded by Bpifrance, which aims to develop new tools and treatments for resistant E. coli infections using precision phage therapy.

Differentiator

Problem solved

Functional benefit

Products and services

  • PhagECOLI A three-year research program developing precision phage therapy tools and treatments for antibiotic-resistant Escherichia coli infections, conducted in partnership with CEA and funded by a €2 million grant from Bpifrance.

Companies that use Pherecydes Pharma

Customer profile

Segments1 record

Ideal customer profiles2 records

Pherecydes Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Pherecydes Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CEA (Commissariat à l'énergie atomique et aux énergies alternatives)coreStrategic or Co-development PartnerPherecydes Pharma collaborates with CEA on the PhagECOLI project, a three-year research initiative focused on developing new tools and treatments for resistant E. coli infections using precision phage therapy. The partnership leverages CEA's research capabilities in atomic energy and alternative energies.

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Pherecydes Pharma competitors and assessment

Company assessment

Direct peers

  • BiomX: Clinical-stage phage therapy company developing phage-based treatments for chronic and acute bacterial infections. Directly comparable to Pherecydes in modality (precision phage therapy), target indications (resistant bacterial infections), and stage of development.
  • Locus Biosciences: Clinical-stage company developing engineered bacteriophage therapies, including CRISPR-enhanced phages, for antibiotic-resistant infections. Direct peer in modality, AMR focus, and clinical-stage development.
  • Armata Pharmaceuticals: Clinical-stage phage therapy company developing both natural and engineered phage cocktails for resistant bacterial infections including Staphylococcus aureus and Pseudomonas aeruginosa. Direct peer in phage modality and AMR focus.
  • ContraFect: Biotech developing direct lytic agents and phage-derived lysins for serious antibiotic-resistant infections. Comparable to Pherecydes in pursuing novel antimicrobial modalities against resistant bacterial pathogens.
  • Eligo Bioscience: Developer of engineered phage-based therapeutics (eligobiotics) targeting specific bacterial pathogens. Comparable to Pherecydes in precision phage platform approach and focus on selectively eradicating disease-causing bacteria.

Regional players

  • TechnoPhage: Portugal-based clinical-stage phage therapy developer working on personalized and fixed phage cocktails for resistant bacterial infections. Comparable to Pherecydes in modality and AMR focus, but operating primarily in Southern Europe/Portugal rather than France.

Emerging players

  • Phagelux: Phage-based biotech developing therapeutic and agricultural applications of bacteriophages. Comparable to Pherecydes in phage platform technology, though with a broader agricultural/industrial portfolio alongside human health.
  • Micreos: Developer of phage-based products including Gladskin for skin conditions and food-safety applications. Comparable to Pherecydes in underlying phage technology platform but currently focused on consumer/dermatology rather than systemic resistant infections.
  • SNIPR Biome: Biotech using CRISPR-engineered phage and microbial approaches to precisely target bacteria. Comparable to Pherecydes in using precision phage-derived mechanisms to address resistant bacterial populations.
  • Cytophage Technologies: Canadian biotech developing synthetic biology-based phage products targeting resistant bacteria in human and animal health. Comparable to Pherecydes in leveraging engineered phage approaches against AMR pathogens.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Pherecydes Pharma social profiles

Digital presence

Pherecydes Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pherecydes Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Pherecydes Pharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pherecydes Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pherecydes Pharma

What does Pherecydes Pharma do?

Pherecydes Pharma is a French biotechnology company developing precision phage therapy (bacteriophage-based treatments) to combat antibiotic-resistant bacterial infections. Its lead research program, the PhagECOLI project, focuses on creating phage-based tools and treatments targeting resistant Escherichia coli infections. The company is at the R&D stage, conducting research in collaboration with CEA and funded by Bpifrance and venture capital investors.

Is Pherecydes Pharma a public or private company?

Pherecydes Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pherecydes Pharma founded?

Pherecydes Pharma was founded in 2006. It employs 1 to 10 people.

Where is Pherecydes Pharma based?

Pherecydes Pharma is headquartered in Nantes, France, in the Europe region.

Who are Pherecydes Pharma's main competitors?

Direct peers on record are BiomX, Locus Biosciences, Armata Pharmaceuticals, ContraFect and Eligo Bioscience. TechnoPhage is listed as a regional player. Emerging players are Phagelux, Micreos, SNIPR Biome and Cytophage Technologies.

Does Pherecydes Pharma have an API?

No public API is recorded for Pherecydes Pharma.

What industry is Pherecydes Pharma in?

Pherecydes Pharma's product category is Biopharmaceuticals (Phage Therapy). Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireERYTECH and PHERECYDES announce merger and name change to PHAXIAM TherapeuticsERYTECH and PHERECYDES merged to form PHAXIAM Therapeutics, approved by shareholders with a large majority. The company will develop extended phage therapies targeting antimicrobial-resistant bacteria, with a Phase 2 trial in knee or hip prosthetic joint infections anticipated in Q1 2024. A 10-for-1 reverse stock split is expected.GlobeNewswireERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023ERYTECH shareholders approved the merger with Pherecydes and renamed the company Phaxiam Therapeutics. The merger uses an exchange ratio of 4 Pherecydes shares for 15 Erytech shares, with new shares trading on Euronext Paris on June 29, 2023.GlobeNewswireERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes PharmaThe Lyon Commercial Court rejected Akkadian's request to postpone the vote on Erytech's merger with Pherecydes Pharma. Shareholders can now vote on June 23, 2023, and an expert appraisal must be completed within four months, with Akkadian covering costs.BenzingaErytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes CloserErytech Pharma is facing opposition from activist investor Akkadian Partners regarding its proposed merger with Pherecydes Pharma, with Akkadian seeking to postpone the shareholder vote originally scheduled for June 23. The merger would absorb Pherecydes into publicly listed Erytech, with Pherecydes shareholders receiving 15 new Erytech shares for every four of their current shares, while Erytech has warned that derailing the deal would risk destroying value for both companies. Akkadian, which owns approximately 5% of Erytech, argues the company has sufficient financial resources to continue independently and contends the merger would serve as a "death warrant" for Erytech shareholders.GlobeNewswireERYTECH Responds to Akkadian’s DisinformationERYTECH responded to Akkadian Partners' disinformation campaign opposing its merger with PHERECYDES, calling the activist's arguments incomplete and misleading. The company defended the exchange ratio, citing an independent appraiser's validation, and urged shareholders to vote for the merger at the June 23 general meeting.GlobeNewswireERYTECH announces the availability of the exemption document relating to the proposed combination with PherecydesERYTECH Pharma announced the publication of an exemption document relating to its proposed combination with Pherecydes. The document is available on the company's website in the Shareholders Meeting section. The combination was announced on February 15, 2023.GlobeNewswireERYTECH Provides Update on the Announced Combination with PHERECYDESERYTECH and PHERECYDES entered a merger agreement on May 15, 2023, with PHERECYDES shareholders receiving 15 ERYTECH shares for every 4 PHERECYDES shares. A contribution of 827,132 PHERECYDES shares was completed, and the merger will be submitted to shareholders' vote on June 23, 2023.GlobeNewswireERYTECH Provides Business and Financial Update for theERYTECH Pharma provided its Q1 2023 business and financial update, confirming the merger with Pherecydes to create a global phage therapy leader, with a shareholder vote expected in June. The company held €30.5 million in cash and cash equivalents as of March 31, 2023, and will not provide interim quarterly P&L information.GlobeNewswireERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022ERYTECH Pharma reported a net loss of €0.2 million for full year 2022, a €53.7 million improvement, and held €38.8 million in cash at year-end. The company sold its U.S. manufacturing facility to Catalent for $44.5 million and announced a strategic combination with Pherecydes to pursue phage therapy.Business Wire BlogFollowing the Announcement of Its Proposed Merger With Erytech, Pherecydes Pharma Completes a €1.5 Million Capital Increase Reserved to Its Historical ShareholdersPherecydes Pharma completed a €1.5 million capital increase reserved for its historical shareholders, including Auriga IV Bioseeds and Ouest Ventures III, following the announcement of its proposed merger with Erytech Pharma. The funds raised will finance the company's cash requirements until the end of H1 2023, supporting operations ahead of the scheduled merger completion by June 30, 2023. This financial move is part of the strategic integration process between the two biotechnology firms.